Appendix NReferences for Summary Tables

Publication Details

1.
Liao Y, McGee DL, Cooper RS. Prediction of coronary heart disease mortality in blacks and whites: pooled data from two national cohorts. Am J Cardiol. 1999;84(1):31–6. [PubMed: 10404847]
2.
Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47. [PubMed: 9603539]
3.
Liao Y, McGee DL, Cooper RS, et al. How generalizable are coronary risk prediction models? Comparison of Framingham and two national cohorts. Am Heart J. 1999;137(5):837–45. [PubMed: 10220632]
4.
D'Agostino RB Sr, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286(2):180–7. [PubMed: 11448281]
5.
Berry JD, Lloyd-Jones DM, Garside DB, et al. Framingham risk score and prediction of coronary heart disease death in young men. Am Heart J. 2007;154(1):80–6. [PMC free article: PMC2279177] [PubMed: 17584558]
6.
D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743–53. [PubMed: 18212285]
7.
Wilson PW, Bozeman SR, Burton TM, et al. Prediction of first events of coronary heart disease and stroke with consideration of adiposity. Circulation. 2008;118(2):124–30. [PubMed: 18591432]
8.
Gaziano TA, Young CR, Fitzmaurice G, et al. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet. 2008;371(9616):923–31. [PMC free article: PMC2864150] [PubMed: 18342687]
9.
Miyasaka Y, Barnes ME, Gersh BJ, et al. Coronary ischemic events after first atrial fibrillation: risk and survival. Am J Med. 2007;120(4):357–63. [PubMed: 17398231]
10.
Vaidya D, Yanek LR, Moy TF, et al. Incidence of coronary artery disease in siblings of patients with premature coronary artery disease: 10 years of follow-up. Am J Cardiol. 2007;100(9):1410–5. [PMC free article: PMC2128738] [PubMed: 17950799]
11.
Mainous AG 3rd, Everett CJ, Player MS, et al. Importance of a patient's personal health history on assessments of future risk of coronary heart disease. J Am Board Fam Med. 2008;21(5):408–13. [PubMed: 18772295]
12.
Chambless LE, Heiss G, Shahar E, et al. Prediction of ischemic stroke risk in the Atherosclerosis Risk in Communities Study. Am J Epidemiol. 2004;160(3):259–69. [PubMed: 15257999]
13.
Folsom AR, Chambless LE, Duncan BB, et al. Prediction of coronary heart disease in middle-aged adults with diabetes. Diabetes Care. 2003;26(10):2777–84. [PubMed: 14514579]
14.
Mainous AG 3rd, Koopman RJ, Diaz VA, et al. A coronary heart disease risk score based on patient-reported information. Am J Cardiol. 2007;99(9):1236–41. [PMC free article: PMC1931421] [PubMed: 17478150]
15.
McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk In Communities study. Diabetes Care. 2005;28(2):385–90. [PubMed: 15677797]
16.
Lee ET, Howard BV, Wang W, et al. Prediction of coronary heart disease in a population with high prevalence of diabetes and albuminuria: the Strong Heart Study. Circulation. 2006;113(25):2897–905. [PubMed: 16769914]
17.
Greenland P, LaBree L, Azen SP, et al. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291(2):210–5. [PubMed: 14722147]
18.
Detrano RC, Wong ND, Doherty TM, et al. Coronary calcium does not accurately predict near-term future coronary events in high-risk adults. Circulation. 1999;99(20):2633–8. [PubMed: 10338455]
19.
Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006;145(1):21–9. [PubMed: 16818925]
20.
Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297(6):611–9. [PubMed: 17299196]
21.
Bernard S, Serusclat A, Targe F, et al. Incremental predictive value of carotid ultrasonography in the assessment of coronary risk in a cohort of asymptomatic type 2 diabetic subjects. Diabetes Care. 2005;28(5):1158–62. [PubMed: 15855582]
22.
Dunder K, Lind L, Zethelius B, et al. Evaluation of a scoring scheme, including proinsulin and the apolipoprotein B/apolipoprotein A1 ratio, for the risk of acute coronary events in middle-aged men: Uppsala Longitudinal Study of Adult Men (ULSAM) Am Heart J. 2004;148(4):596–601. [PubMed: 15459588]
23.
Strom Moller C, Zethelius B, Sundstrom J, et al. Persistent ischaemic ECG abnormalities on repeated ECG examination have important prognostic value for cardiovascular disease beyond established risk factors: a population-based study in middle-aged men with up to 32 years of follow-up. Heart. 2007;93(9):1104–10. [PMC free article: PMC1955011] [PubMed: 17483125]
24.
Erikssen G, Bodegard J, Bjornholt JV, et al. Exercise testing of healthy men in a new perspective: from diagnosis to prognosis. Eur Heart J. 2004;25(11):978–86. [PubMed: 15172470]
25.
Reissigova J, Zvarova J. The Framingham risk function underestimated absolute coronary heart disease risk in Czech men. Methods Inf Med. 2007;46(1):43–9. [PubMed: 17224979]
26.
Assmann G, Schulte H, Cullen P, et al. Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study. Eur J Clin Invest. 2007;37(12):925–32. [PubMed: 18036028]
27.
Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study. Circulation. 2002;105(3):310–5. [PubMed: 11804985]
28.
Assmann G, Schulte H, Seedorf U. Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) study. Int J Obes (Lond) 2008;32(Suppl 2):S11–S6. [PubMed: 18469834]
29.
Ferrario M, Chiodini P, Chambless LE, et al. Prediction of coronary events in a low incidence population: assessing accuracy of the CUORE Cohort Study prediction equation. Int J Epidemiol. 2005;34(2):413–21. [PubMed: 15659467]
30.
Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC) Heart. 2007;93(2):172–6. [PMC free article: PMC1861393] [PubMed: 17090561]
31.
Cooper JA, Miller GJ, Humphries SE. A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study. Atherosclerosis. 2005;181(1):93–100. [PubMed: 15939059]
32.
Macfarlane PW, Norrie J. The value of the electrocardiogram in risk assessment in primary prevention: experience from the West of Scotland Coronary Prevention Study. J Electrocardiol. 2007;40(1):101–9. [PubMed: 17069838]
33.
Stephens JW, Ambler G, Vallance P, et al. Cardiovascular risk and diabetes: are the methods of risk prediction satisfactory? Eur J Cardiovasc Prev Rehabil. 2004;11(6):521–8. [PubMed: 15580065]
34.
Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336(7659):1475–82. [PMC free article: PMC2440904] [PubMed: 18573856]
35.
Simmons RK, Sharp S, Boekholdt SM, et al. Evaluation of the Framingham risk score in the European Prospective Investigation of Cancer–Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events? Arch Intern Med. 2008;168(11):1209–16. [PubMed: 18541829]
36.
Vergnaud AC, Bertrais S, Galan P, et al. Ten-year risk prediction in French men using the Framingham coronary score: results from the national SU.VI.MAX cohort. Prev Med. 2008;47(1):61–5. [PubMed: 18456313]
37.
Bastuji-Garin S, Deverly A, Moyse D, et al. The Framingham prediction rule is not valid in a European population of treated hypertensive patients. J Hypertens. 2002;20(10):1973–80. [PubMed: 12359975]
38.
Marrugat J, Subirana I, Comin E, et al. Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study. J Epidemiol Community Health. 2007;61(1):40–7. [PMC free article: PMC2465597] [PubMed: 17183014]
39.
Donnan PT, Donnelly L, New JP, et al. Derivation and validation of a prediction score for major coronary heart disease events in a U.K. type 2 diabetic population. Diabetes Care. 2006;29(6):1231–6. [PubMed: 16732001]
40.
Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007;335(7611):136. [PMC free article: PMC1925200] [PubMed: 17615182]
41.
Becker A, Leber A, Becker C, et al. Predictive value of coronary calcifications for future cardiac events in asymptomatic individuals. Am Heart J. 2008;155(1):154–60. [PubMed: 18082507]
42.
de Ruijter W, Westendorp RG, Assendelft WJ, et al. Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ. 2009;338:a3083. [PMC free article: PMC2615548] [PubMed: 19131384]
43.
Cederholm J, Eeg-Olofsson K, Eliasson B, et al. Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register. Diabetes Care. 2008;31(10):2038–43. [PMC free article: PMC2551651] [PubMed: 18591403]
44.
May M, Lawlor DA, Brindle P, et al. Cardiovascular disease risk assessment in older women: can we improve on Framingham? British Women's Heart and Health prospective cohort study. Heart. 2006;92(10):1396–401. [PMC free article: PMC1861043] [PubMed: 16547204]
45.
Barzi F, Patel A, Gu D, et al. Cardiovascular risk prediction tools for populations in Asia. J Epidemiol Community Health. 2007;61(2):115–21. [PMC free article: PMC2465638] [PubMed: 17234869]
46.
Jee SH, Park JW, Lee SY, et al. Stroke risk prediction model: a risk profile from the Korean study. Atherosclerosis. 2008;197(1):318–25. [PubMed: 17586511]
47.
Liu J, Hong Y, D'Agostino RB Sr, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA. 2004;291(21):2591–9. [PubMed: 15173150]
48.
Wu Y, Liu X, Li X, et al. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults. Circulation. 2006;114(21):2217–25. [PubMed: 17088464]
49.
Yang X, So WY, Kong AP, et al. Development and validation of a total coronary heart disease risk score in type 2 diabetes mellitus. Am J Cardiol. 2008;101(5):596–601. [PubMed: 18308005]
50.
Yang X, So WY, Kong AP, et al. Development and validation of stroke risk equation for Hong Kong Chinese patients with type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care. 2007;30(1):65–70. [PubMed: 17192335]
51.
Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J. 1991;121(1 Pt 2):293–8. [PubMed: 1985385]
52.
Anderson KM, Wilson PW, Odell PM, et al. An updated coronary risk profile: a statement for health professionals. Circulation. 1991;83(1):356–62. [PubMed: 1984895]
53.
Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003. [PubMed: 12788299]
54.
Kothari V, Stevens RJ, Adler AI, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke. 2002;33(7):1776–81. [PubMed: 12105351]
55.
Paynter NP, Chasman DI, Buring JE, et al. Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med. 2009;150(2):65–72. [PMC free article: PMC2629586] [PubMed: 19153409]
56.
Simons LA, Simons J, Friedlander Y, et al. Risk functions for prediction of cardiovascular disease in elderly Australians: the Dubbo Study. Med J Aust. 2003;178(3):113–6. [PMC free article: PMC3133925] [PubMed: 12558481]
57.
Pyorala K, De Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J. 1994;15(10):1300–31. [PubMed: 7821306]
58.
1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. Dyslipidaemia Advisory Group on behalf of the scientific committee of the National Heart Foundation of New Zealand. N Z Med J. 1996;109(1024):224–31. [PubMed: 8769031]
59.
Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118(22):2243–51. [PMC free article: PMC2752381] [PubMed: 18997194]
60.
Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15(4):827–32. [PubMed: 2407762]
61.
Hense HW, Schulte H, Lowel H, et al. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany—results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J. 2003;24(10):937–45. [PubMed: 12714025]
62.
Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. Heart. 2008;94(1):34–9. [PubMed: 17916661]
63.
Denes P, Larson JC, Lloyd-Jones DM, et al. Major and minor ECG abnormalities in asymptomatic women and risk of cardiovascular events and mortality. JAMA. 2007;297(9):978–85. [PubMed: 17341712]
64.
Weiner DE, Tighiouart H, Elsayed EF, et al. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol. 2007;50(3):217–24. [PubMed: 17631213]
65.
Arad Y. Beyond traditional risk factor analysis for coronary artery disease: the case for coronary artery calcium assessment with electron beam computed tomography. Prev Cardiol. 2002;5(2):62–7. [PubMed: 11986549]
66.
Stern MP, Williams K, Gonzalez-Villalpando C, et al. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care. 2004;27(11):2676–81. [PubMed: 15505004]
67.
Orford JL, Sesso HD, Stedman M, et al. A comparison of the Framingham and European Society of Cardiology coronary heart disease risk prediction models in the normative aging study. Am Heart J. 2002;144(1):95–100. [PubMed: 12094194]
68.
Grover SA, Dorais M, Paradis G, et al. Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines. CMAJ. 2000;163(10):1263–9. [PMC free article: PMC80320] [PubMed: 11107461]
69.
Ducloux D, Kazory A, Chalopin JM. Predicting coronary heart disease in renal transplant recipients: a prospective study. Kidney Int. 2004;66(1):441–7. [PubMed: 15200454]
70.
Brindle PM, McConnachie A, Upton MN, et al. The accuracy of the Framingham risk-score in different socioeconomic groups: a prospective study. Br J Gen Pract. 2005;55(520):838–45. [PMC free article: PMC1570792] [PubMed: 16281999]
71.
Lindman AS, Veierod MB, Pedersen JI, et al. The ability of the SCORE high-risk model to predict 10-year cardiovascular disease mortality in Norway. Eur J Cardiovasc Prev Rehabil. 2007;14(4):501–7. [PubMed: 17667638]
72.
Wannamethee SG, Shaper AG, Lennon L, et al. Metabolic syndrome vs Framingham risk sScore for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005;165(22):2644–50. [PubMed: 16344423]
73.
Brindle P, Emberson J, Lampe F, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ. 2003;327(7426):1267. [PMC free article: PMC286248] [PubMed: 14644971]
74.
Buyken AE, von Eckardstein A, Schulte H, et al. Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study. Eur J Cardiovasc Prev Rehabil. 2007;14(2):230–6. [PubMed: 17446801]
75.
Koenig W, Lowel H, Baumert J, et al. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment—results from a large cohort study in southern Germany. Circulation. 2004;109(11):1349–53. [PubMed: 15023871]
76.
Ulmer H, Kollerits B, Kelleher C, et al. Predictive accuracy of the SCORE risk function for cardiovascular disease in clinical practice: a prospective evaluation of 44649 Austrian men and women. Eur J Cardiovasc Prev Rehabil. 2005;12(5):433–41. [PubMed: 16210929]
77.
Scheltens T, Verschuren WM, Boshuizen HC, et al. Estimation of cardiovascular risk: a comparison between the Framingham and the SCORE model in people under 60 years of age. Eur J Cardiovasc Prev Rehabil. 2008;15(5):562–6. [PubMed: 18756178]
78.
Silventoinen K, Pankow J, Lindstrom J, et al. The validity of the Finnish Diabetes Risk Score for the prediction of the incidence of coronary heart disease and stroke, and total mortality. Eur J Cardiovasc Prev Rehabil. 2005;12(5):451–8. [PubMed: 16210931]
79.
Vliegenthart R, Oudkerk M, Hofman A, et al. Coronary calcification improves cardiovascular risk prediction in the elderly. Circulation. 2005;112(4):572–7. [PubMed: 16009800]
80.
Empana JP, Ducimetiere P, Arveiler D, et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J. 2003;24(21):1903–11. [PubMed: 14585248]
81.
Milne R, Gamble G, Whitlock G, et al. Discriminative ability of a risk-prediction tool derived from the Framingham Heart Study compared with single risk factors. N Z Med J. 2003;116(1185):U663. [PubMed: 14615805]
82.
Wang Z, Hoy WE. Is the Framingham coronary heart disease absolute risk function applicable to Aboriginal people? Med J Aust. 2005;182(2):66–9. [PubMed: 15651963]
83.
Bhopal R, Fischbacher C, Vartiainen E, et al. Predicted and observed cardiovascular disease in South Asians: application of FINRISK, Framingham and SCORE models to Newcastle Heart Project data. J Public Health (Oxf) 2005;27(1):93–100. [PubMed: 15749725]
84.
Koller MT, Steyerberg EW, Wolbers M, et al. Validity of the Framingham point scores in the elderly: results from the Rotterdam study. Am Heart J. 2007;154(1):87–93. [PubMed: 17584559]
85.
McEwan P, Williams JE, Griffiths JD, et al. Evaluating the performance of the Framingham risk equations in a population with diabetes. Diabet Med. 2004;21(4):318–23. [PubMed: 15049932]
86.
Guzder RN, Gatling W, Mullee MA, et al. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed type 2 diabetes: results from a United Kingdom study. Diabet Med. 2005;22(5):554–62. [PubMed: 15842509]
87.
Becker A, Leber AW, Becker C, et al. Predictive value of coronary calcifications for future cardiac events in asymptomatic patients with diabetes mellitus: a prospective study in 716 patients over 8 years. BMC Cardiovasc Disord. 2008;8:27. [PMC free article: PMC2569906] [PubMed: 18847481]
88.
Elkeles RS, Godsland IF, Feher MD, et al. Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study. Eur Heart J. 2008;29(18):2244–51. [PubMed: 18573867]
89.
Suka M, Sugimori H, Yoshida K. Application of the updated Framingham risk score to Japanese men. Hypertens Res. 2001;24(6):685–9. [PubMed: 11768728]
90.
Suka M, Sugimori H, Yoshida K. Validity of the Framingham risk model applied to Japanese men. Methods Inf Med. 2002;41(3):213–5. [PubMed: 12162145]
91.
Arad Y, Goodman KJ, Roth M, et al. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. J Am Coll Cardiol. 2005;46(1):158–65. [PubMed: 15992651]
92.
Carty CL, Cushman M, Jones D, et al. Associations between common fibrinogen gene polymorphisms and cardiovascular disease in older adults. The Cardiovascular Health Study. Thromb Haemost. 2008;99(2):388–95. [PubMed: 18278190]
93.
Komorovsky R, Desideri A. Carotid ultrasound assessment of patients with coronary artery disease: a useful index for risk stratification. Vasc Health Risk Manag. 2005;1(2):131–6. [PMC free article: PMC1993944] [PubMed: 17315399]